The aim of the study is to evaluate the side effects and risks after infusion of retroviral
gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned
(busulphan)patients with chronic granulomatous disease (CGD). Also gene corrected and
functional active granulocytes in the peripheral blood and the engraftment in the bone marrow
of the patients will be monitored an documented.